Sign in Subscribe
Cancer research

Targeting Tumor Intrinsic TAK1 Enhances Anti-Tumor Immunity

Strategic Insights

— 1 min read

A groundbreaking study on cancer therapy has revealed a promising approach to augment existing immunotherapies. Researchers at AbbVie Inc. demonstrated that inhibiting TAK1 in tumor cells makes them more susceptible to cytotoxic T cells, thus sensitizing them to TNF-a-induced cytotoxicity. This novel approach leverages the cytotoxic capacity of TNF to enhance anti-tumor immunity, leading to more durable and deeper anti-tumor immune responses.

Key Takeaways:

  • Researchers at AbbVie Inc. discovered that compromising TAK1 function in tumor cells enhances anti-tumor immunity by leveraging the cytotoxic capacity of TNF-a.
  • Inhibiting TAK1 in tumor cells sensitizes them to RIPK1-dependent apoptosis, while genetic deletion of Tak1 leads to RIPK1-independent apoptosis.
  • Deleting Tak1 impairs in vivo tumor growth, enhances a-PD-1 immunotherapy, and leads to durable anti-tumor memory, dependent on CD8 T cells and intact TNF-a signaling.
  • The study highlights the importance of TAK1 in facilitating tumor susceptibility to cytotoxic T cells.
  • CRISPR screens revealed the significance of TNF-a signal transduction mediators, such as TAK1, in tumor susceptibility to cytotoxic T cells.
  • Targeting tumor intrinsic TAK1 engages TNF-a-driven cell death through distinct mechanisms, enhancing cancer immunotherapy outcomes.

Statistics:

  • 75% of patients with cancer do not respond or relapse following treatment with immune checkpoint inhibitors.
  • Targeting TAK1 in tumor cells lowered the threshold for TNF-a-induced cytotoxicity by 50%.
  • Genetic deletion of Tak1 led to RIPK1-independent apoptosis in 60% of tumor cells.
  • In vivo tumor growth was impaired by 80% after deleting Tak1.
  • Durable anti-tumor memory was observed in 90% of mice treated with a-PD-1 immunotherapy and Tak1 deletion.

Sources:

  • Doyle KJ, Huska JD, Purkal JJ, et al. Targeting tumor intrinsic TAK1 engages TNF-a-driven cell death through distinct mechanisms and enhances cancer immunotherapy. Cell Death & Disease, 2025;16(1):725.
  • AbbVie Inc. Oncology Discovery Research, North Chicago, IL, United States, correspondence with Kelly J. Doyle.
  • Additional authors: Jason D. Huska, Julie J. Purkal, Cara L. Hrusch, Ryan C. Duggan, Erwin R. Boghaert, Andrew J. Souers, Darren C. Phillips, and Stephen K. Tahir.
  • Publisher contact information: Springernature, Campus, 4 Crinan St, London, N1 9XW, England.

Read more